Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli-D Study.
Diabetes Obes MetabJul 19, 2026 (epub)
Saichun Zhang, Yunjuan Gu, Yu Cheng et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis of the Soli-D study evaluated the efficacy and safety of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) versus insulin degludec plus insulin aspart (IDegAsp) in 582 Chinese adults with type 2 diabetes. At 24 weeks, iGlarLixi demonstrated greater reductions in HbA1c compared to IDegAsp, with no significant interactions based on age, disease duration, or HbA1c levels.
Key findings
- iGlarLixi resulted in greater HbA1c reductions compared to IDegAsp at Week 24.
- Total daily insulin doses were consistently lower with iGlarLixi across all subgroups.
- Hypoglycaemia event rates were reduced with iGlarLixi compared to IDegAsp in all subgroups.
Why it matters
The findings suggest that iGlarLixi may offer a more effective and safer treatment option for managing glycaemic control in Chinese adults with type 2 diabetes, particularly for those inadequately controlled on oral medications.